Integrative Proteomic Characterization of Pancreatic Ductal Adenocarcinoma

Ruijin Hospital200 enrolled

Overview

A large-scale, high-throughput, multi-dimensional comprehensive study of PDAC multiomics will be carried out. In this study, clinical specimens of resected PDAC collected by our research group from 2017 to 2019 will be selected as research objects.Tumor tissues and their adjacent non-tumor tissues from more than 200 PDAC patients are expected to be used for genome, transcriptome sequencing and mass spectrometry analysis of proteome and phosphorylated proteome.Combined with the data results of multiomics, bioinformatics analysis and network database information, we will clarify the relationship between multiomics of pancreatic cancer and established the new subtyping of pancreatic cancer proteome. A molecular landscape of the progression of pancreatic cancer at the genome-transcriptome-proteome level provides new therapeutic targets to improve the prognosis of this deadly disease.

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Tumor Tissues and Non-tumor Tissues From PDAC Patients Were Used for Genomic and Transcriptome Sequencing Analysis and Proteomics and Phosphorylated Proteomics

Interventions

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. The diagnosis of pancreatic cancer was confirmed by histological examination or fine needle aspiration cytology; 2. The tumor was graded according to THE WHO standard, and the tumor stage was graded according to the TNM stage; Exclusion Criteria: 1. The inclusion criteria of the above groups were not met; 2. There are few tissue specimens, only enough for clinical diagnosis; 3. Patients are unwilling to conduct follow-up study; 4. For the new diagnosed patient, radiotherapy or chemotherapy have been given in the previous three months;

Outcomes

Primary Outcomes

Integrative Proteomic Characterization of PDAC

The genome-transcriptome proteome level provides a molecular landscape of the progression of pancreatic cancer, providing new therapeutic targets to improve the prognosis of PDAC

Time frame: Two yeaers

Central Contacts

Hao Chen, MD

CONTACT

13003135899 haochendr@126.com

Lingxi Jiang, Ph.D